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Abstract
In 2012 the Centers for Disease Control and Prevention recommended routine testing for hepatitis 
C for people born in the period 1945–65. Until now, the recommendation’s impact on hepatitis C 
screening rates in the United States has not been fully understood. We used an interrupted time 
series with comparison group design to analyze hepatitis C screening rates in the period 2010–14 
among 2.8 million commercially insured adults in the MarketScan database. Hepatitis C screening 
rates increased yearly between 2010 and 2014, from 1.65 to 2.59 per 100 person-years. A 49 
percent increase in screening rates among people born during 1945–65 followed the release of the 
recommendation, but no such increase was observed among adults born after 1965. The effect 
among the target population was sustained, and by twenty-four months after the 
recommendation’s release, screening rates had increased 106 percent. We conclude that the 
hepatitis C testing policy change resulted in significantly increased testing among the target 
population and may have decreased the magnitude of the hepatitis C epidemic.
Infection with the hepatitis C virus is associated with significant morbidity and mortality, 
with more than 19,000 annual deaths related to hepatitis C in the United States.1,2 In the 
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period 2003–13 the number of deaths related to hepatitis C exceeded those related to sixty 
other infectious diseases combined.1 In 2015 people ages 55–64 accounted for half of the 
deaths related to hepatitis C in the United States.2 The cost of hepatitis C in the United 
States in 2011 was estimated to be $6.5 billion, a figure that is projected to increase to $9.1 
billion by 2024.3
In 1998 the Centers for Disease Control and Prevention (CDC) recommended that people at 
high risk for transmission of hepatitis C be tested for the virus.4 However, the risk-based 
testing strategy had limited effectiveness, as shown by the substantial proportion of people 
who were unaware that they were infected.5 In recognition of the disproportionately high 
prevalence of hepatitis C among people born in the period 1945–65,6,7 the CDC released a 
new recommendation in August 2012: All people in this birth cohort should receive a one-
time test for hepatitis C without previous assessment of their risk for the disease.8 In 2013 
the US Preventive Services Task Force gave this recommendation a “B” rating, which 
motivated insurers to provide coverage for screening in the birth cohort.9
Despite these changes, birth cohort screening rates vary depending on patient 
population.10–12 Analyses of national trends in hepatitis C testing have shown significant 
increases in testing among the birth cohort in the period following the recommendation 
change,13,14 but the specific causal impact of this policy change on clinical practice has not 
been evaluated. Improvements in testing can lead to increased case finding, decreased 
hepatitis C transmission, and earlier initiation of antiviral treatment among infected persons, 
thus reducing morbidity and mortality related to hepatitis C.15–17 We analyzed hepatitis C 
screening rates in the United States in the period 2010–14, using a strong quasi-experimental 
design to determine the causal impact of the 2012 recommendation on rates of testing 
among people with commercial insurance in the birth cohort.
Study Data And Methods
Data Source
We analyzed data for the period 2010–14 from the MarketScan Commercial Claims and 
Encounters database, a commercial health insurance database managed by Truven Health 
Analytics. This database includes approximately one billion insurance claims per year from 
more than a hundred US commercial insurance plans for the continuum of outpatient and 
inpatient care for people younger than age sixty-five. While the database does not include 
information about every person in the United States, it does cover all enrollees in nearly half 
of the employer sponsored health insurance plans in the US. Previous studies have found 
that the people in the database are representative of the commercially insured US 
population.18 The claims data include Current Procedural Terminology (CPT) codes and 
dates of service and are linked to patient demographic characteristics such as age, sex, and 
geographic region of residence (Northeast, North Central, South, and West).
Inclusion And Exclusion Criteria
We included claims for hepatitis C screening events for all adults ages eighteen and older. 
We studied two cohorts: the birth cohort, defined as adults born in the period 1945–65 (as 
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explained above), and the complement cohort, defined as adults born after 1965 but at least 
age eighteen. We defined a hepatitis C screening event as a claim for an hepatitis C virus 
antibody test (using CPT codes 86803, for a hepatitis C virus antibody test; 86804, for a 
hepatitis C virus antibody confirmatory test; and 80059, for a hepatitis panel test) that 
occurred at least thirty days after the most recent previous hepatitis C virus antibody test for 
a given individual.
We assumed that two or more hepatitis C tests obtained within a thirty-day period would 
represent a single screening event. Two or more hepatitis C tests obtained within a 
subsequent thirty-day period would represent another screening event. For example, an 
antibody test for the virus obtained by one provider might represent the true screening test, 
while a subsequent referral to a subspecialist might elicit a second antibody test if records 
for the first test were unavailable. The second test should be considered a confirmatory test 
rather than a screening test.
We calculated the number of times that two or more antibody tests were obtained in a thirty-
day period for people born in 1964 or 1966. We found that this phenomenon occurred 601 
times for people born in 1964 and 549 times for persons born in 1966. Given the relatively 
small number of occurrences, we concluded that excluding these occurrences as screening 
events would probably not impact our overall findings.
We defined hepatitis C diagnostic testing and evaluation as antibody tests that were likely 
ordered to either confirm a recent positive test or as part of preparation for hepatitis C 
treatment. We excluded from analysis the following claims: those for people whose first 
claim in the database related to hepatitis C was for hepatitis C RNA, hepatitis C genotype, or 
a clinic visit for hepatitis C; and those for people who had previous claims for hepatitis C 
treatment, RNA, or genotype.
Statistical Analysis
We used an interrupted time series with comparison group design to analyze quarterly 
hepatitis C screening rates in the MarketScan data for the period January 2010–December 
2014. This particular quasi-experimental design is regarded as one of the strongest designs 
to assess causal inference based on observational data.19
The August 2012 release of the CDC recommendation for one-time hepatitis C testing 
among US adults in the birth cohort was the intervention of interest. The quarterly hepatitis 
C screening rate was the outcome of interest. We determined the number of months per year 
that people were enrolled in a health plan in the database by age cohort. This resulted in 
person-months, which we divided by 12 to calculate person-years. We used Akaike 
information criteria to determine that a negative binomial regression model provided the best 
fit, compared to other models.20
Because the CDC’s hepatitis C testing recommendation was released in August 2012, we 
defined the third quarter of 2012 as the transition quarter and excluded it from the analysis. 
The pre-intervention period began on January 1, 2010, and ended on June 30, 2012 (the end 
of the second quarter), and the post-intervention period began on October 1, 2012 (the 
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beginning of the fourth quarter), and ended on December 31, 2014. The final models 
included nineteen time points (ten for the pre-intervention quarters and nine for the post-
intervention quarters).
We fit a series of regression models. The initial model included terms for year of birth (birth 
cohort versus complement cohort), intervention (pre-intervention period versus post-
intervention period), and secular time trends for periods before and after the intervention, as 
well as interaction terms for these individual terms (for regression model results, see online 
Appendix Exhibit A1).21 Our second model assessed whether there were significant 
differences after the intervention between men and women in the birth cohort. Our final 
model estimated the relationship between screening rates and region of residence for people 
in the birth cohort.
We modeled the screening rates in the first post-intervention quarter (immediate) as well as 
twelve and twenty-four months after the intervention. To quantify the impact of the 
recommendation on screening rates, we compared the expected rate of screening over time 
(calculated from the model) to the projection of pre-intervention trends (as if the guidelines 
had not changed). As a result, our analysis accounted for secular trends that were present 
before the recommendation was released. Rate ratios of the estimated and expected rates and 
the percentage changes were calculated.
A two-sided p value of less than 0.05 was considered significant. Statistical analyses were 
performed using R version 3.3.2 and SAS version 9.4.
Limitations
There were several limitations to our study. First, hepatitis C screening events were 
identified based on CPT codes and our definition of a screening event, which could be 
subject to miscategorization. However, antibodies are the preferred screening test in the 
United States, and we included CPT codes that contained the hepatitis C virus antibody. In 
addition, we found very few instances in which there was more than one screening test 
ordered in a single thirty-day period. This would indicate that we were selecting only true 
screening events and not simply confirmatory testing or testing by a different provider.
Second, the MarketScan database includes only people with commercial insurance—not 
those with governmental insurance such as Medicare or Medicaid. Nor does the database 
include information on race or ethnicity, so no evaluation of confounding by these variables 
was possible. Previous studies in key populations have demonstrated that there are racial and 
ethnic differences in hepatitis C screening, so our results might not be generalizable to 
populations less well represented in the MarketScan database.11 Future studies of hepatitis C 
screening trends and the impact of recommendations should use databases that include 
information on these demographic characteristics.
Finally, while we used a strong quasi-experimental design for causal inference, we could not 
rule out the possibility of unmeasured confounders that may exist in any observational study.
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Study Results
In the period 2010–14, there were 3,204,010 hepatitis C screening events in the MarketScan 
database (Exhibit 1). Thirty-three percent of the events were for people in the birth cohort, 
and 67 percent were for those in the complement cohort. The total number of yearly 
screening events increased from 479,399 in 2010 to 791,787 in 2014. In the study period, the 
birth cohort accounted for 43 percent of the total person-years, and the complement cohort 
accounted for 57 percent.
Hepatitis C screening rates in the US population increased each year in the study period, 
from 1.65 per 100 person-years in 2010 to 2.59 per 100 person-years in 2014 (Exhibit 1). 
The screening rates in the birth cohort initially increased modestly, but they increased 
markedly from 2012 to 2014 (Exhibits 1 and 2). In comparison, the screening rates in the 
complement cohort increased only modestly throughout the study period, although this 
cohort started with higher screening rates.
In the two-group interrupted time series model, there was a significant change in hepatitis C 
screening rates following the recommendation in the birth cohort but not in the complement 
cohort. While screening rates in both age groups increased during the period, there was a 49 
percent additional increase in the immediate post-intervention period in the birth cohort (risk 
ratio: 1.49) that was not observed in the complement cohort (RR: 1.00) (Exhibit 3).
As noted above, the trend in rising screening rates within the birth cohort turned sharply 
higher in the years following the 2012 recommendation, whereas there was no significant 
change in trend within the complement cohort (Exhibit 2). We examined two additional 
specific time points, twelve and twenty-four months after the intervention. In the birth 
cohort, there was an increase of more than a 100 percent in screening rates at twenty-four 
months, relative to what would have been predicted in the absence of the intervention (RR: 
2.06) (Exhibit 3). No difference was observed in the complement cohort at that time point, 
relative to what would have been predicted in the absence of the intervention (RR: 0.99).
We next evaluated whether in the birth cohort the intervention had a different impact among 
men and women, and among people in different geographical regions. We found no 
difference in the screening rates between men (1.07 per 100 person-years) and women (1.11 
per 100 person-years) in the pre-intervention period (data not shown). We also found no 
difference in the impact of the intervention on screening rates by sex: Men and women both 
had significant increases in screening rates in the post-intervention period compared to the 
pre-intervention period, but they did not differ from each other at any time point (for 
example, in the fourth quarter of 2012, the risk ratios were 1.42 for men and 1.47 for 
women) (Exhibit 3).
The 2012 recommendation that members of the birth cohort be tested for hepatitis C resulted 
in increases in screening rates in all regions of the United States, although different patterns 
of change were observed across regions (Exhibit 4). In the Northeast, there was only a 29 
percent increase in screening rates in the immediate post-intervention period, but at twenty-
four months after the intervention, screening rates had increased by 134 percent. Conversely, 
in the West there was an initial increase of 73 percent in screening rates, but the longer-term 
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change in trend was less pronounced than in the Northeast (an increase of 55 percent at 
twenty-four months). The North Central and South regions had gradual, modest increases in 
screening rates over the post-intervention period.
Discussion
We assessed the impact of the 2012 CDC recommendation that all adults born in the period 
1945–65 be tested once for hepatitis C, and we found a significant increase in and 
acceleration of hepatitis C screening uptake among the target population. We confirmed that 
there was no significant change after 2012 in the screening trends among adults born after 
1965, which supports to the conclusion that the observed changes are likely related to the 
CDC recommendation rather than to a general secular trend. Based on the birth cohort’s 
estimated 3.2 percent prevalence of hepatitis C,6 the overall testing effect may be translated 
into an estimated 118,000 additional cases of hepatitis C identified among the birth cohort 
by the end of 2014 that were attributable to the change in testing recommendations. This is a 
substantial number of cases, given the estimated total burden of hepatitis C in the birth 
cohort.6
We used a robust quasi-experimental design that provides strong evidence for a causal effect 
of the recommendation on the observed increases in screening. Our findings complement 
those of Cheryl Isenhaur and coauthors, who observed a 2.5-fold increase in hepatitis C 
virus antibody testing in the period 2005–14—with the greatest increases seen in the birth 
cohort.13 Our findings also complement another analysis that demonstrated increases in 
hepatitis C testing among the birth cohort following the release of the 2013 US Preventive 
Services Task Force recommendation.14 We note that there was a secular trend of increasing 
screening rates in the US population and in each age group before the CDC’s 
recommendation. Possible drivers of the observed change could include increasing 
awareness of hepatitis C among patients and clinicians, the availability of new oral 
medications, and the expansion of the number of people with health care under the 
Affordable Care Act.
We found a steep increase in screening rates among the birth cohort in the quarter 
immediately following release of the CDC’s recommendation that did not appear in the 
complement cohort. Furthermore, we found that the difference in trends between the two 
groups became greater over time: While the rate of increase continued to grow in the birth 
cohort, the complement cohort experienced no change in the rate of increase. Our analysis 
allowed for a continued secular trend in both age groups, but we identified and quantified the 
independent effect of the hepatitis C testing recommendation on screening rates.
We also observed that before 2012, the complement cohort had higher screening rates than 
the birth cohort. The higher initial screening rates in the complement cohort likely reflect 
previous recommendations for risk-based screening. The large increase that we observed in 
the birth cohort screening rates after the CDC’s guidance changed demonstrates the potential 
for recommendations for routine hepatitis C screening to expand the reach of hepatitis C 
diagnosis. Furthermore, the fact that screening rates among the complement cohort did not 
go down after 2012 suggest that there has not been detrimental competition between routine 
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and risk-based testing guidelines. Studies of the impact of other policy changes that used 
similar methodology have also observed abrupt changes in the post-intervention period.22,23 
Our study is significant because it further demonstrates, on a national level, both an 
immediate and sustained impact of hepatitis C testing guidelines on clinical practice.
Our findings differ from smaller studies that have evaluated the impact of interventions to 
improve screening. These studies show gradual increases in screening rates that are often not 
sustained after, for example, the implementation of electronic reminders.24–26 These studies 
cite patient, provider, and societal barriers to the implementation of guidelines, which can 
include a lack of knowledge about the guidelines.24–27 We acknowledge that such barriers 
exist and could explain why the post-intervention screening rates we found were not higher. 
Perhaps if those barriers had been addressed, screening rates in the post-intervention period 
would have increased even more.
We also evaluated the effect of the testing recommendation on sex and geographic region of 
residence. We found no disparities based on sex in the change in screening rates following 
the intervention, which is consistent with a previous study that found only slightly higher 
screening rates among female veterans than males (58.2 percent versus 54.5 percent).11 
However, another study found that male veterans were more likely than females to be tested 
for hepatitis C.28 Both studies reported screening rates that were considerably higher than 
the national screening rates we found. These differences may be a result of the effective 
programs that the Department of Veterans Affairs has implemented to reduce barriers to 
implementation of the testing recommendation. Our findings highlight the need to address 
systemic barriers to further improve hepatitis C screening rates on the national level.
The guidelines had a more sizable effect in the Northeast, compared to the other three 
regions of the United States. This may be due to issues related to access to medical care, 
including preventive services, and availability of health insurance. Regional variation in the 
uptake of recommendations on a number of health interventions has previously been 
documented.29,30 Additionally, Sourik Sarkar and coauthors found significant regional 
variability in hepatitis C testing.28 Taken together, these findings suggest the need for 
region-specific programs to augment guidelines to further improve screening.
The screening recommendation appears to have been a success, raising the question of 
whether screening rates would similarly increase if hepatitis C recommendations were 
expanded to include additional age groups. When the birth cohort recommendation was 
released, it was widely known that the highest hepatitis C prevalence in the United States 
was among people in that cohort.31 At the time, it was estimated that three-quarters of all 
people living with hepatitis C and 70 percent of all those whose deaths were associated with 
hepatitis C were in this cohort.32 This recommendation was appropriate given the high 
prevalence and cost-effectiveness of birth cohort screening.33 The hepatitis C epidemic has 
changed, however, and the greatest incidence of infection is now among young people who 
inject drugs, due to the tremendous spike in injection opioid use among that population.34–38 
For instance, 77 percent of the young people who had nearly 1,200 incident hepatitis C 
infections in the period 2006–12 reported using injection drugs.39 While people who inject 
drugs are included in CDC recommendations as members of a high-risk group who should 
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be screened, we know from previous studies that risk-based screening has been inadequate 
in the past in identifying hepatitis C infection.40 With the knowledge that guidelines do 
affect clinical practice, now may be the time to consider expansion of the hepatitis C 
screening guidelines. We acknowledge that achieving universal screening will be difficult 
given the growing syndemic of hepatitis C and opioid use disorder.
Conclusion
We found that the 2012 CDC recommendation that people born in the period 1945–65 be 
tested for hepatitis C had a significant impact on screening trends. Our causal design allowed 
us to separate the impact of the recommendation from the secular screening trends 
attributable to other factors. These results contribute to the body of evidence that health 
policy recommendations can affect clinical practice. However, screening for and identifying 
hepatitis C infection are just the first steps in the continuum of care. Further expansion of 
hepatitis C testing recommendations and the development of region-specific approaches to 
address barriers to implementation could lead to increased treatment and significantly 
improve clinical outcomes associated with hepatitis C in the United States.
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Exhibit 2. 
Trends in quarterly hepatitis C screening rates in the United States per 100 person-years in 
2010–14, by age group
Source/Notes: SOURCE Authors’ analysis of data from the MarketScan Commercial 
Claims and Encounters database managed by Truven Health Analytics. NOTES “Person-
years,” “birth cohort,” and “complement cohort” are defined in the Notes to Exhibit 1. “Q” 
indicates quarter-year. Because the Centers for Disease Control and Prevention released its 
recommendation that all members of the birth cohort be tested for hepatitis C in August 
2012, we treated the third quarter of 2012 as the transition quarter and excluded it from our 
analysis. The trend lines show observed data. The 95% confidence intervals (the shaded 
areas around each trend line) were modeled using a negative binomial regression model.
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Exhibit 4. 
Trends in quarterly hepatitis C screening rates per 100 person-years in the United States in 
2010–14 for people in the birth cohort, by geographic region of residence
Source/Notes: SOURCE Authors’ analysis of data from the MarketScan Commercial 
Claims and Encounters database managed by Truven Health Analytics. NOTES “Person-
years” and “birth cohort” are defined in the Notes to Exhibit 1. “Q” indicates quarter-year. 
The transition quarter is explained in the Notes to Exhibit 2. The trend lines show observed 
data. The 95% confidence intervals (the shaded areas around each trend line) were modeled 
using a negative binomial regression model.
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Exhibit 3
Risk ratios (RRs) of hepatitis C screening in the United States before and after the birth cohort testing 
recommendation
Fourth quarter of:
2012 2013 2014
Age group (overall)
Birth cohort 1.49** 1.75** 2.06**
Complement cohort 1.00 0.99 0.99
Birth cohort by sex
Females 1.47* 1.68** 1.93**
Males 1.42** 1.61** 1.82***
Birth cohort by geographic region
Northeast 1.29** 1.74*** 2.34***
North Central 1.45* 1.71** 1.99**
South 1.36** 1.48** 1.62**
West 1.73* 1.64** 1.55**
SOURCE Authors’ analysis of data from the MarketScan Commercial Claims and Encounters database managed by Truven Health Analytics. 
NOTES The Centers for Disease Control and Prevention recommended in August 2012 that all members of the birth cohort be tested for hepatitis 
C. Because the fourth quarter of 2012 was the first full quarter of the intervention period, we assessed the intervention’s impact in the fourth 
quarters of subsequent years. “Birth cohort” and “complement cohort” are defined in the Notes to Exhibit 1. Risk ratios are calculated by 
comparing the screening rate at each time point in the presence of the intervention to the predicted screening rate at each time point in the absence 
of the intervention. Significance refers to differences between the screening rate in the presence of the intervention and the predicted screening rate 
in the absence of the intervention.
*p < 0.10
**p < 0.05
***p < 0.01
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